Hansa Biopharma AB (HNSBF)
2.93
0.00 (0.00%)
USD |
OTCM |
Sep 20, 16:00
Hansa Biopharma EPS Diluted (Quarterly): -0.3094 for June 30, 2024
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.3094 |
| March 31, 2024 | -0.4001 |
| December 31, 2023 | -0.2204 |
| September 30, 2023 | -0.4431 |
| June 30, 2023 | -0.4559 |
| March 31, 2023 | -0.3761 |
| December 31, 2022 | -0.3005 |
| September 30, 2022 | -0.3291 |
| June 30, 2022 | -0.3904 |
| March 31, 2022 | -0.3338 |
| December 31, 2021 | -0.4167 |
| September 30, 2021 | -0.3867 |
| June 30, 2021 | -0.3545 |
| March 31, 2021 | -0.2795 |
| December 31, 2020 | -0.2756 |
| September 30, 2020 | -0.3129 |
| June 30, 2020 | -0.2565 |
| March 31, 2020 | -0.2423 |
| December 31, 2019 | -0.2885 |
| September 30, 2019 | -0.2462 |
| June 30, 2019 | -0.2181 |
| Date | Value |
|---|---|
| March 31, 2019 | -0.1976 |
| December 31, 2018 | -0.231 |
| September 30, 2018 | -0.18 |
| June 30, 2018 | -0.1791 |
| March 31, 2018 | -0.1518 |
| December 31, 2017 | -0.161 |
| September 30, 2017 | -0.1304 |
| June 30, 2017 | -0.1454 |
| March 31, 2017 | -0.1423 |
| December 31, 2016 | -0.1084 |
| September 30, 2016 | -0.0974 |
| June 30, 2016 | -0.1145 |
| March 31, 2016 | -0.0722 |
| December 31, 2015 | -0.0682 |
| September 30, 2015 | -0.0507 |
| June 30, 2015 | -0.0831 |
| March 31, 2015 | -0.0469 |
| December 31, 2014 | -0.0633 |
| September 30, 2014 | -0.0288 |
| June 30, 2014 | -0.0273 |
| March 31, 2014 | -0.0402 |
Earnings per Share Definition
Earnings per share measures the total net income / average shares outstanding during income period. There are a few variations to earnings per share that are listed including "EPS Basic", "EPS Diluted", "Normalized Basic EPS", and "Normalized Diluted EPS". Each of these metrics are dependent on which earnings and shares outstanding metrics are used. Basic and Diluted EPS differ in that diluted shares are the amount of shares outstanding after all convertible securities, options, and warrants are exercised. Normalized EPS allows does not include one-time expenses.
EPS Diluted (Quarterly) Range, Past 5 Years
-0.4559
Minimum
Jun 2023
-0.2204
Maximum
Dec 2023
-0.3309
Average
-0.321
Median
EPS Diluted (Quarterly) Benchmarks
| Abliva AB | -0.0019 |
| Karolinska Development AB | -0.0056 |
| Calliditas Therapeutics AB | -0.165 |
| Oncopeptides AB | -0.0417 |
| BioInvent International AB | -0.1959 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.49M |
| Revenue (Quarterly) | 3.219M |
| Total Expenses (Quarterly) | 20.79M |
| Enterprise Value | 222.22M |
| Gross Profit Margin (Quarterly) | -18.04% |
| Profit Margin (Quarterly) | -605.6% |
| Earnings Yield | -46.86% |
| Normalized Earnings Yield | -46.86 |